Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vyne Therapeutics : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Drug Trial

10/05/2021 | 09:29am EST


ę MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
11/18VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confer..
AQ
11/10VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/10VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/10VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
PU
11/10VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
11/10VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
AQ
11/10Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $4.1M, vs. Street Est of $4.76..
MT
11/10Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Loss $-0.36, vs. Street Est of $-0.3..
MT
11/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/04Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a..
PU
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 16,7 M - -
Net income 2021 -68,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,75x
Yield 2021 -
Capitalization 55,1 M 55,1 M -
Capi. / Sales 2021 3,31x
Capi. / Sales 2022 7,90x
Nbr of Employees 106
Free-Float 92,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,03 $
Average target price 5,00 $
Spread / Average Target 385%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-83.23%57
JOHNSON & JOHNSON1.82%421 847
ROCHE HOLDING AG17.17%334 769
PFIZER, INC.38.25%285 639
NOVO NORDISK A/S68.76%247 704
ELI LILLY AND COMPANY55.18%237 527